Sign up to receive the weekly WA Innovation Calendar Newsletter!  Sign up here
X

Tag: Life Sciences

CSIRO Conversations: Quantum for Every Business

Quantum is moving fast and it’s already creating real opportunities for Australian businesses. This event unpacks what’s real and what’s coming next.

Quantum is at the same stage AI was a decade ago, quietly moving from research labs into real world tools. This event helps industry understand what’s real, what’s hype, and where the near term opportunities lie and who can help. Where today’s computers check one option at a time, quantum can explore many possibilities at once. That makes it powerful for decision making and resource management when it comes to things like routing trucks, detecting minerals, managing patients in a hospital, securing communications or modelling new materials.

Quantum is becoming practical and commercially relevant far sooner than most businesses expect. It’s already emerging in:

  • Supply chains: quantum inspired optimisation is helping logistics companies reduce fuel use and manage disruptions.
  • Finance: banks are exploring quantum safe encryption to protect transactions.
  • Quantum sensing: ultra precise measurements for mining, agriculture, health and defence.

Our expert panellists will translate a complex emerging technology into a grounded, industry relevant discussion on:

  • What quantum technologies can do today.
  • What’s coming next.
  • How Australian businesses can prepare responsibly and competitively.
  • How quantum intersects with supply chain resilience, national security, and economic pressures.

Pre-submit your questions to the expert panellists ahead of the webinar

From IP to Investment: What Investors Look for in a Patent Portfolio

The first session in Victorian Medtech Skills and Devices Hub’s 2026 Medtech Skills Online Spotlight Series, this free lunchtime webinar will show you how investors assess your IP and how to position it to support funding.

If you’re developing a medtech idea, securing investment depends on more than the innovation itself. Investors look closely at your patent position to assess risk, ownership, and commercial potential.

This session will show you what matters and how to avoid common IP gaps that can delay or block funding. You’ll learn how investors assess these key areas of your patent portfolio and what to prioritise.

WALSIH presents: BioCina Open Door Session

Go behind the scenes, meet experts, and explore partnership and career pathways at a leading Australian CDMO.

BioCina is a global Contract Development and Manufacturing Organisation (CDMO) with deep expertise in small molecules, biologics (microbial, pDNA, mRNA, LNP modalities) delivering integrated drug substance and drug product manufacturing from two GMP facilities in Australia. The Perth facility specialises in sterile fill-finish, covering drug product formulation, aseptic filling and finish operations across multiple formats. With internationally approved facilities and highly experienced teams, BioCina supports innovators from early development through to commercial supply.

This ‘Open Door Session’ of BioCina’s state-of-the-art 14,000m² Perth facility offers a unique opportunity to engage directly with BioCina’s technical experts and a first‑hand look at sterile drug product filling in action.

Attendees will gain insights into manufacturing workflows, quality systems and what collaboration and workforce pathways with BioCina could look like.

Virtual Global Expert Program: Jennifer Head

​This session will explore how innovators can develop a credible and practical strategy for entering the NHS market.

​While many companies focus heavily on regulatory approval and clinical evidence, successful NHS adoption depends on a much broader set of commercial, operational, and system-level factors.

​Drawing on real-world experience supporting MedTech innovators, we will explore:

  • ​How NHS decision-making works across clinicians, commissioners, procurement teams, and integrated care systems
  • ​The different commercial pathways into the NHS and how to determine which is most appropriate for your technology
  • ​Why strong clinical evidence alone is rarely enough to drive adoption
  • ​Common strategic mistakes innovators make when approaching the NHS market
  • How to realistically assess whether the NHS represents a viable and scalable commercial opportunity

2026 Medtech Masterclasses

The Medtech Masterclasses is a one-day, two-stream, high-impact program delivering practical, real-world insights across the entire medtech lifecycle. With more than 15 curated sessions, the program brings together experts and leaders from across the medtech ecosystem to help founders, startups, industry participants, and post-PhD researchers turn innovative ideas into clinical and commercial success.

The program is structured into two focused streams:

  • Developing Technical Readiness: covering product development, regulatory pathways, clinical trials, and technical innovation.
  • Developing Commercial Readiness: covering business strategy, fundraising, market access, and commercialisation.

Building on the success of the 2024 program, the 2026 Medtech Masterclasses will feature leading local and international experts from top organisations, offering hands-on learning, actionable strategies, and valuable networking opportunities that drive meaningful impact across the medtech sector.

A networking session and dinner will be held after the event, providing an additional opportunity to connect with speakers, peers, and industry leaders. Tickets for the networking dinner are available separately or as part of a package.

The Medtech Masterclasses is an official satellite event of AusMedtech.

Off the Record | Real Stories of Medtech

Ready to unwind after AusMedTech? Or couldn’t make it but still want to connect with the WA medtech community? This is the event for you.

Join us for a short, lively panel hosted by Dr Michael Challenor, where medtech founders share their real, unfiltered “pound the table” moments – the highs, the setbacks, and everything in between.

We don’t often talk about failure in Australia, but behind every “overnight success” is a story of persistence, pivots and lessons learned. This is your chance to hear those stories, stripped back and honest, from those who’ve lived them.

Grab a drink, enjoy great food and music, and settle into an evening of relaxed networking. Whether you’re a founder, researcher, investor or industry professional, it’s the perfect setting to connect, swap stories and meet others in the ecosystem.

Expect a fun, informal (and slightly chaotic) night that goes beyond the usual event format. Don’t miss it – secure your ticket now.

UWA Data Institute – Research Bytes | Discover. Engage. Connect.

Join us for a dynamic Research Bytes session held each semester by the UWA Data Institute, where UWA researchers showcase the latest developments across data-driven science, engineering, health, and the humanities.

This event highlights how innovative research is tackling complex challenges, fostering cross-disciplinary collaboration, and unlocking new opportunities for industry engagement.

From emerging ideas to applied solutions, this session offers a unique glimpse into the breadth and impact of data-driven research happening right here in WA. Whether you’re in academia, industry, or simply curious about where data meets impact, this is an event you won’t want to miss.

DEADLINE: AusSRC HPC Funding Applications Close

The Australian SKA Regional Centre (AusSRC) is proud to launch the Astronomy Resources for Industry Applications (ARIA) Program, a new initiative designed to accelerate innovation through access to high-performance computing (HPC).
AusSRC is Australia’s contribution to the international SKA Regional Centre Network (SRCNet). The SRCNet will support the global flow of data and processing needed for the SKA telescopes – the two most advanced radio telescopes in the world, located in Australia and South Africa.
One of AusSRC’s goals is to support discovery and delivery of impact beyond radio astronomy. By working with industry to foster data-intensive innovations across sectors, AusSRC aims to leverage astronomy capabilities to generate broad benefits to the Australian economy and community.

The ARIA Program has been established to provide Australian start-ups and small to medium businesses with access to HPC resources to enable innovation in products and services aligned with key technical priorities.

For the 2026 inaugural funding round, AusSRC will support projects focused on:

  • Data Management
  • Data Visualisation
  • Data Compression

We are seeking applications from SMEs and start-ups that would benefit from HPC capability but face barriers accessing research-based or large-scale infrastructure schemes.

Applications are open to organisations from any industry excluding astronomy that can demonstrate how covering HPC-related expenses would directly enable innovation in one or more of the priority areas.

For a full explanation of the ARIA Program, please refer to the ARIA Program Guidelines and ARIA Program Frequently Asked Questions (FAQs).

‘Morning Tea & Learn’ with Dr Greydon Gilmore

Join this event to hear from Dr Greydon Gilmore, a Canadian neurophysiology expert visiting Perth to connect with WA’s biomedical community.

This talk will highlight Greydon’s innovative work developing open-source software to help neurosurgeons plan and evaluate surgical procedures. The goal was to make these tools more practical, accurate, and easier to use in real clinical settings. By bringing together medical imaging, brain signal data, and software development, this work aimed to translate complex research methods into real world tools that can directly support patient care. More broadly, it shows the entrepreneurial opportunity to build surgical technologies that can improve precision and create new opportunities for innovation in healthcare.

This event is ideal for researchers, clinicians, and innovators interested in neurophysiology, imaging, biomedical engineering, or translational neuroscience.

DEADLINE: Investor Readiness Program (IRP)

AusBiotech Investor Readiness Program (IRP) is officially open for year round applications. This is a brilliant opportunity for companies from discovery stage teams to ASX listed entities to gain structured investor informed feedback on their translational pathway and capital positioning at no cost.

For ASX-listed life sciences companies, the IRP can help sharpen how milestones, evidence and capital needs are communicated to the market. It is designed to support clearer investor-facing positioning at a time when many companies are working to align development progress with capital strategy. AusBiotech’s IRP provides structured, investor-informed feedback to help life sciences companies strengthen their translational pathway and capital positioning — from early development through to institutional readiness. There is no cost to apply and you do not need to be a member.

To be considered for the Early Stage Innovation Forum at AusMedtech 2026 or AusBiotech Invest Perth please ensure your submission is in by 23 March.